Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled study of BW-00112 in severe hypertriglyceridemia
CTR20240713Phase 2Completed
- Sponsor
- Bolin Pharma
- Start
- Apr 2024
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of BW-00112 in hypertriglyceridemia (4 arms), sponsored by Bolin Pharma. Primary endpoint: Percent change from baseline in fasting triglycerides at Day 180. Started Apr 2024; status: completed.
02
Drugs
BW-00112
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on CTR20240713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240713.